In-vivo proof of concept achieved by targeting of IL1RAP on human tumor

Lund, Sweden 02 February 2012. Cantargia AB announced today that the concept of targeting IL1RAP has been further validated and extended to solid tumors, this time in-vivo. A Cantargia-developed anti-IL1RAP monoclonal antibody showed highly significant inhibition of tumor growth in an in-vivo model of transplanted human malignant melanoma.

The company has previously presented significant anti-malignant effects in an ex-vivo model of human leukemia. The project is based on the original discovery of IL1RAP as a unique receptor on leukemic stem cells in patients with Chronic Myeloid Leukemia (CML). The IL1RAP receptor has also been shown to be up-regulated on stem cells of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

“These results validate the concept in-vivo as well as represent an additional therapeutic target for an antibody based therapy against IL1RAP” said Agneta Svedberg, CEO of Cantargia.

About Cantargia AB
Cantargia AB is a research and development company based on the original discovery at Lund University and operates under the novel model of LU Bioscience aiming to reduce operational and financial risks normally associated with early preclinical drug development. Cantargia is focused on developing a conceptually new therapy for the treatment of hematological malignancies (leukemia).

For more information on Cantargia visit www.cantargia.com.